Skip to main content
Caplight Logo









Arexera Therapeutics

Arexera Therapeutics

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://arexeratx.com

Last Round

Series B

Jan 28, 2025

Total Funding Raised

$97M

Company Overview

Arexera Therapeutics is a clinical-stage biotechnology company developing siRNA medicines for severe neurological diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

small interfering RNAsiRNAgene silencingHuntington's diseaseRNAi therapeuticsRNA interferenceneurological diseasesneurodegenerative disordersdivalent siRNAdi-siRNAbispecific siRNAbi-siRNAbiotechdrug discoveryCNS therapeuticsgene therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Arexera Therapeutics Comparables

Compare Arexera Therapeutics with similar companies based on industry and business-model similarity.

Arexera Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Skyhawk Therapeutics
87%
Aerska
83%
Vico Therapeutics
82%

Arexera Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJan 28, 2025
Series AJan 11, 2021

Arexera Therapeutics Investors

Notable investors and investment history

Arexera Therapeutics investors
InvestorRounds
EQT Life SciencesSeries B
Mirae AssetSeries B
abrdn Inc.Series B
GenentechSeries A
GHR FoundationSeries B
RiverVest Venture PartnersSeries B
Pictet Alternative AdvisorsSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 28, 2025

    $97M round led by Sanofi Ventures and EQT Life Sciences.

  • Jan 11, 2021

    Round led by F-Prime Capital with participation from Biogen and Genentech.

Arexera Therapeutics Filings

Explore SEC and related filing metadata, where available.

Arexera Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Arexera Therapeutics's valuation, stock price, and market status.

Is Arexera Therapeutics a public or private company?

Arexera Therapeutics is a private company.

What is the current stock price of Arexera Therapeutics?

Arexera Therapeutics is a private company, so its shares have no public market price. Caplight tracks Arexera Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Arexera Therapeutics worth (valuation)?

Valuation information for Arexera Therapeutics is not publicly available.

Can I buy Arexera Therapeutics stock?

Arexera Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Arexera Therapeutics's last funding round?

Arexera Therapeutics's most recent funding round was Series B on January 28, 2025.

Who are the main investors in Arexera Therapeutics?

Key investors in Arexera Therapeutics include EQT Life Sciences, F-Prime Capital, Sanofi Ventures.

Will Arexera Therapeutics IPO soon?

No public IPO plans have been announced for Arexera Therapeutics.

How can I track Arexera Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades in Arexera Therapeutics's shares on secondary markets.

Firmographic Details

HeadquartersBoston, Massachusetts
Year FoundedN/A
Last FundingJan 28, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?